The Scientific Advisory Committee provides technical expertise on drug research, development, manufacturing, and distribution, as well as other medical and scientific issues. It consists of twelve scientific experts from a wide range of relevant disciplines, including:
- Drug Discovery: genomics, microbiology, molecular biology, medicinal chemistry and pharmacology;
- Drug development: medicinal chemistry, preclinical development, formulation and manufacturing experts;
- Clinical expertise: internal medicine, infectious diseases, and clinical trials;
- Clinical trials in TB-endemic countries;
- Epidemiology;
- Pharmaceutical and biotechnology industries; and
- Statistics
Members of the Scientific Advisory Committee are selected for three-year terms. To address myriad scientific and technical needs, the Chair has the flexibility to invite scientists to serve as ad hoc members for limited periods of time, or on a project-by-project basis.
|
|
Scientific Advisory Committee Members
 Prof. Stewart Cole
Ecole Polytechnique Fédérale de Lausanne Dr. Michael Dunne
Durata Therapeutics, Inc Dr. Mark Goldberger
Abbott Laboratories Dr. Frank L. Hurley
RRD International, LLC Dr. Stefan Kaufmann
Max Planck Institute for Infection-Biology Dr. Richard Losick
Harvard University Dr. G. Lynn Marks (Chair)
GlaxoSmithKline Prof. Lester A. Mitscher
University of Kansas Dr. Valerie Mizrahi
National Health Lab Service & University of the Witwatersrand Dr. Paranji R. Narayanan
 Dr. Paul Reider
Princeton University Dr. Eric Rubin
Harvard School of Public Health Dr. Christine Sizemore
National Institute of Allergy & Infectious Diseases Dr. Eve E. Slater
|
